Zobrazeno 1 - 5
of 5
pro vyhledávání: '"David F. Claxton"'
Autor:
Todd E. Fox, Mark Kester, Hong Gang Wang, Shantu Amin, Charyguly Annageldiyev, Gemma Fabriàs, Jennifer M. Pearson, David J. Feith, Dhimant Desai, Thomas P. Loughran, José Luis Abad, Su Fern Tan, Myles C. Cabot, David F. Claxton, Arati Sharma
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Mol Cancer Res
instname
Mol Cancer Res
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation of immature myeloid cells in the blood and bone marrow. The 5-year survival rate is approximately 25%, and recent therapeutic developments have yielded little survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1bdd7205bbbd915f8f5818c777254c
http://hdl.handle.net/10261/212229
http://hdl.handle.net/10261/212229
Autor:
Amriti R. Lulla, Jeffrey J. Pu, Jawad Babar, Nadia Khan, Cyril H. Benes, Lanlan Zhou, Joshua E. Allen, A. Pieter J. van den Heuvel, Ultan McDermott, Mala K. Talekar, Mathew J. Garnett, C. Leah B. Kline, Junior Hall, Wolfgang Oster, David F. Claxton, Varun V. Prabhu, David T. Dicker, Wafik S. El-Deiry, Stephan A. Grupp
Publikováno v:
Cell Cycle. 17:468-478
ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ON
Autor:
Wangsen Cao, Christine A. Kelley, Nancy A. Speck, Martin Britos-Bray, Alan D. Friedman, David F. Claxton, Pengfei Liu
Publikováno v:
Oncogene. 15:1315-1327
CBF beta-SMMHC is expressed from the inv(16) chromosome in M4Eo AML. Mice lacking CBF subunits or expressing the CBF beta-SMMHC or AML1-ETO oncoproteins failed to develop definitive hematopoiesis. To investigate these effects on hematopoiesis, we exp
Autor:
Tonya S. King, Marcela Jimenez, Jong K. Yun, Michael G. Bayerl, Elizabeth J. Conroy, Richard Bruggeman, Jeremy A. Hengst, David F. Claxton
Publikováno v:
Leukemialymphoma. 49(5)
Sphingosine kinase 1 (SphK1) is an oncoprotein capable of directly transforming cells and is associated with resistance to chemotherapy and radiotherapy. SphK1 is increased in various human cancers; whereas, blockade restores sensitivity to therapeut
Autor:
Amriti R. Lulla, Liz J. Hernandez-Borrero, Jeffrey J. Pu, Jessica Wagner, Mala K. Talekar, Joshua E. Allen, Varun V. Prabhu, David T. Dicker, Brian M. Barth, Wafik S. El-Deiry, David F. Claxton, Christina Leah B. Kline
Publikováno v:
Blood. 124:5237-5237
ONC201/TIC10 is a potent small molecule anti-tumor agent in several types of solid tumors and lymphomas. ONC201/TIC10 is on track to enter clinical trials for patients with advanced cancer in 2014, with IND issued by the FDA in March, 2014. Early tri